FY2025 Earnings Forecast for TNYA Issued By Lifesci Capital

Key Points

• Lifesci Capital trimmed its FY2025 EPS estimate for Tenaya to ($0.75) (from ($0.74)) and projects Q4 FY2025 EPS of ($0.17), versus a MarketBeat consensus full-year loss of ($1.35).
• Other analysts have lowered targets—HC Wainwright to $3 and Chardan to $8—while Weiss Ratings keeps a sell; the stock's consensus rating is a Moderate Buy with a $5.50 target.
• Shares fell about 12.8%, opening at $0.67 (52-week range $0.36–$2.35) with a market cap near $111M, and institutional investors now own roughly 90.54% of the company.

Tenaya Therapeutics, Inc. (NASDAQ:TNYA - Free Report) - Equities researchers at Lifesci Capital reduced their FY2025 EPS estimates for Tenaya Therapeutics in a research note issued on Tuesday, December 16th. Lifesci Capital analyst C. Jubinville now anticipates that the company will earn ($0.75) per share for the year, down from their previous forecast of ($0.74). The consensus estimate for Tenaya Therapeutics' current full-year earnings is ($1.35) per share. Lifesci Capital also issued estimates for Tenaya Therapeutics' Q4 2025 earnings at ($0.17) EPS.

Other analysts also recently issued reports about the company. HC Wainwright decreased their price target on Tenaya Therapeutics from $5.00 to $3.00 and set a "buy" rating for the company in a research report on Friday, December 12th. Chardan Capital reduced their price objective on Tenaya Therapeutics from $9.00 to $8.00 and set a "buy" rating for the company in a research note on Friday, December 12th. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Tenaya Therapeutics in a research report on Wednesday, October 8th. Four analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $5.50.

Tenaya Therapeutics Stock Down 12.8%

Tenaya Therapeutics stock opened at $0.67 on Thursday. Tenaya Therapeutics has a 52 week low of $0.36 and a 52 week high of $2.35. The company's 50 day moving average price is $1.43 and its two-hundred day moving average price is $1.12. The stock has a market cap of $111.06 million, a P/E ratio of -0.86 and a beta of 3.13.

Tenaya Therapeutics (NASDAQ:TNYA - Get Free Report) last released its quarterly earnings results on Monday, November 10th. The company reported ($0.12) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.03.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Scientech Research LLC purchased a new stake in Tenaya Therapeutics in the 3rd quarter worth about $27,000. Mirador Capital Partners LP increased its stake in shares of Tenaya Therapeutics by 38.2% in the third quarter. Mirador Capital Partners LP now owns 23,500 shares of the company's stock worth $38,000 after purchasing an additional 6,500 shares in the last quarter. DAFNA Capital Management LLC bought a new stake in shares of Tenaya Therapeutics in the first quarter valued at approximately $27,000. Jefferies Financial Group Inc. bought a new stake in shares of Tenaya Therapeutics in the third quarter valued at approximately $99,000. Finally, Persistent Asset Partners Ltd purchased a new stake in shares of Tenaya Therapeutics during the 3rd quarter valued at approximately $117,000. Hedge funds and other institutional investors own 90.54% of the company's stock.

About Tenaya Therapeutics

Tenaya Therapeutics, Inc, a biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States. It develops its products through gene editing, cellular regeneration, and gene addition. The company is developing TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy which is in phase 1 clinical trial; TN-301, a small molecule for heart failure with preserved ejection fraction which is in phase 1 clinical trial; and TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy which is in preclinical stage.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.